Is it Time to Transform Our Treatment Of Type 2 Diabetes
This meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2013-10-01
|
| Series: | European Medical Journal Diabetes |
| Subjects: | |
| Online Access: | http://emjreviews.com/wp-content/uploads/Is-it-Time-to-Transform-Our-Treatment-Of-Type-2-Diabetes_-copy.pdf |